Epidemiology of the first-ever cardiovascular event in people with type 1 diabetes: a retrospective cohort population-based study in Catalonia.
Cerebrovascular disease
Heart failure
Ischemic heart disease
Peripheral vascular disease
Type-1 diabetes; cardiovascular disease
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
14 07 2023
14 07 2023
Historique:
received:
12
05
2023
accepted:
04
07
2023
medline:
17
7
2023
pubmed:
15
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
Knowledge of the characteristics of first-ever cardiovascular events in type 1 diabetes may impact primary prevention strategies. This study describes the first-ever manifestation of cardiovascular disease (CVD) in patients with type 1 diabetes (T1D) in Catalonia (Spain) and evaluates differences according to age and sex. Retrospective cohort study of patients with T1D > 30 years without CVD before 2010 registered in the SIDIAP database. The occurrence of a first cardiovascular event up to the end of 2016, the type of CV event and associations with baseline characteristics were analysed. Of 8412 patients, 884 suffered a first CV event (incidence rate 1.62 per 100 persons-years). Overall, peripheral vascular disease (39.5%) was the most frequent event. We observed a higher proportion of heart failure in women (21.7%) than in men (10.1%). In women, heart failure was the most frequent event in those > 65 years (40.5%). Decreased glomerular filtration rate (hazard ratio [HR] 5.42 [95% CI 4.32;6.80]), elevated albumin/creatinine ratio (HR 3.39 [95% CI [2.47;4.66], microvascular complications (HR 3.27 [95% CI 2.85;3.75]), and hypertension (HR 3.21 [95% CI [2.80;3.67]) were most strongly associated with a first CV event. HbA1c > 7.0% was associated with incident CVD only in patients aged < 55/60 years. Peripheral artery disease in the whole cohort, and heart failure in elder subjects are the most frequent first-ever CVD events in T1D in our region. These findings deserve to be taken into account when considering primary prevention measures and when estimating CV risk in people with T1D.
Sections du résumé
BACKGROUND
Knowledge of the characteristics of first-ever cardiovascular events in type 1 diabetes may impact primary prevention strategies. This study describes the first-ever manifestation of cardiovascular disease (CVD) in patients with type 1 diabetes (T1D) in Catalonia (Spain) and evaluates differences according to age and sex.
METHODS
Retrospective cohort study of patients with T1D > 30 years without CVD before 2010 registered in the SIDIAP database. The occurrence of a first cardiovascular event up to the end of 2016, the type of CV event and associations with baseline characteristics were analysed.
RESULTS
Of 8412 patients, 884 suffered a first CV event (incidence rate 1.62 per 100 persons-years). Overall, peripheral vascular disease (39.5%) was the most frequent event. We observed a higher proportion of heart failure in women (21.7%) than in men (10.1%). In women, heart failure was the most frequent event in those > 65 years (40.5%). Decreased glomerular filtration rate (hazard ratio [HR] 5.42 [95% CI 4.32;6.80]), elevated albumin/creatinine ratio (HR 3.39 [95% CI [2.47;4.66], microvascular complications (HR 3.27 [95% CI 2.85;3.75]), and hypertension (HR 3.21 [95% CI [2.80;3.67]) were most strongly associated with a first CV event. HbA1c > 7.0% was associated with incident CVD only in patients aged < 55/60 years.
CONCLUSIONS
Peripheral artery disease in the whole cohort, and heart failure in elder subjects are the most frequent first-ever CVD events in T1D in our region. These findings deserve to be taken into account when considering primary prevention measures and when estimating CV risk in people with T1D.
Identifiants
pubmed: 37452416
doi: 10.1186/s12933-023-01917-1
pii: 10.1186/s12933-023-01917-1
pmc: PMC10349453
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
179Informations de copyright
© 2023. The Author(s).
Références
Gac Sanit. 2008 May-Jun;22(3):179-87
pubmed: 18579042
Int J Epidemiol. 2022 Dec 13;51(6):e324-e336
pubmed: 35415748
Diabetologia. 2021 Sep;64(9):2001-2011
pubmed: 34106282
Circulation. 2016 Mar 15;133(11):1058-66
pubmed: 26888765
Circulation. 2017 Apr 18;135(16):1522-1531
pubmed: 28416524
Mayo Clin Proc. 2022 Dec;97(12):2271-2281
pubmed: 36272817
Diabetes Care. 2023 Jan 1;46(Suppl 1):S158-S190
pubmed: 36507632
Clin Investig Arterioscler. 2021 Jan-Feb;33(1):19-29
pubmed: 33082056
J Clin Med. 2021 Apr 06;10(7):
pubmed: 33917523
Mayo Clin Proc. 2018 Sep;93(9):1213-1223
pubmed: 29555305
N Engl J Med. 2017 Apr 13;376(15):1407-1418
pubmed: 28402770
JAMA. 2015 Jan 6;313(1):37-44
pubmed: 25562264
Diabetologia. 2022 Jun;65(6):964-972
pubmed: 35314870
Diabetes Care. 2021 Aug;44(8):1885-1893
pubmed: 34162664
Eur Heart J. 2021 Jul 1;42(25):2439-2454
pubmed: 34120177
Diabetes Care. 2016 Jun;39(6):1018-26
pubmed: 27208325
Front Endocrinol (Lausanne). 2022 Jan 10;12:810757
pubmed: 35082758
Diabetes. 2019 Feb;68(2):409-419
pubmed: 30409781
Diabetologia. 2022 Jul;65(7):1169-1178
pubmed: 35411407
Diabetes Care. 2020 Apr;43(4):867-874
pubmed: 32001614
Lancet Diabetes Endocrinol. 2022 Feb;10(2):112-119
pubmed: 35026157
Lancet. 2018 Aug 11;392(10146):477-486
pubmed: 30129464
N Engl J Med. 2014 Nov 20;371(21):1972-82
pubmed: 25409370
Diabetologia. 2006 Apr;49(4):660-6
pubmed: 16432708
Lancet Diabetes Endocrinol. 2015 Mar;3(3):198-206
pubmed: 25660575
N Engl J Med. 2021 May 20;384(20):1921-1930
pubmed: 34010531
Diabetes. 2016 May;65(5):1370-9
pubmed: 26895792
Circulation. 2019 Apr 16;139(16):1900-1912
pubmed: 30798638